先聲藥業(02096.HK)藥品增加新適應症的臨床III期試驗申請獲批

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)藥品增加新適應症的臨床III期試驗申請獲批

阿思達克 03-22 09:15

先聲藥業(02096.HK)公布，其創新生物藥「恩度」獲中國藥監局批准增加新適應症的臨床III期試驗申請，公司將開展有關藥物聯合順鉑對比安慰劑聯合順鉑腔內注射治療惡性胸腹腔積液的隨機、對照、雙盲的多中心Ⅲ期註冊臨床研究。

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)藥品增加新適應症的臨床III期試驗申請獲批

Services

About Us

Agreement Statement